(thirdQuint)ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC).

 ARMS Pharmaceuticals LLC intends to apply for approval of ARMS-I as a prescription drug for the prevention of influenza, rhinovirus and RSV (collectively, "vURTI's).

 The company plans on confirming the limited systemic bioavailability, through conducting a study to characterize the pharmacokinetics of ARMS-I administered orally in healthy adults.

 The primary objective of the study is to determine the pharmacokinetics of ARMS-I following oral administration to healthy subjects.

 Specifically, investigators will assess whether there is measurable systemic exposure and if so, to determine the plasma and pharyngeal fluid pharmacokinetic characteristics of ARMS-I after single and multiple oral dosing.

 The secondary objective will be to evaluate the safety and tolerability of ARMS-I.

.

 ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)@highlight

This is a single center study to evaluate the pharmacokinetics of ARMS-I a formulation that incorporates cetylpyridinium chloride (CPC), administered once as a single dose of three sprays orally, followed by multiple dosing (3x daily oral sprays) over days 3-6 and then a repeat pharmacokinetic study during the final oral dose administered as the first dose on day 7 to ascertain CPC accumulation.

